Bernard J Poiesz, MD

Bernard J Poiesz, MD
Appointed 07/01/74
Women's Health Network
1239 Weiskotten Hall
766 Irving Ave.
Syracuse, NY 13210
315 464-8231

Current Appointments

Hospital Campus

  • Downtown
  • Community

Clinical Section Affiliations

  • Medicine: Hematology and Oncology
  • Medicine - Community Campus: Oncology
  • Upstate Cancer Center: Medical Oncology

Research Programs and Affiliations

  • Cancer Research Institute
  • Medicine


Education & Fellowships

  • Fellowship: National Cancer Institute, NIH, Bethesda, MD, 1977
  • MD: University of Pennsylvania, 1974
  • Residency: University Hospital, SUNY Health Science Center at Syracuse, 1974
  • BA: LaSalle University, 1970

Clinical Interests

  • Oncology, Uro-Oncology; general Hematology

Research Interests

  • Detection, quantification, and characterization of human retro-viruses, testing of antiviral compounds; understanding the biology of sarcomeric protiens.

Clinical Trials

  • Amgen protocol Number: 20070782- A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 ug Once Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
    Read more
  • Avillion Protocol Number AV001: A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
    Read more
  • CALGB 90203:Randomized Phase III Study of Neo-adjuvant Docetaxel and Androgen Deprivation prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
    Read more
  • Celgene Protocol CC-5013-CLL-002: A Phase 3, Multi-center, Randomized, Double-blind, Placebo Controlled, Parallel-group Study of the Efficacy and Safety of Lenalidomide (Revlimid) as Maintenance Therapy for Patients with B-Cell Chronic Lymphocytic Leukemia Following Second-Line Therapy (The CONTINUUM Trial)
    Read more
  • Cerulean Protocol #: CRLX101-208 - A Randomized, Phase 2 Study to Assess the Safety and Efficacy of CRLX101 in Combination With Bevacizumab in Patients With Metastatic Renal Cell Carcinoma (RCC) Versus Standard of Care (SOC) (Investigator's Choice)
    Read more
  • Paroxysmal Nocturnal Hemoglobinuria (PNH) Subject Registry
    Read more
  • Sanofi Protocol No.: OBS13597 - Prospective international observational cohort non-comparative study describing the safety and effectiveness of ZALTRAPĀ® administered in combination with FOLFIRI for the treatment of patients with metastatic colorectal cancer in current clinical practice: A Post-Authorisation Safety Study (PASS)
    Read more

Specialties & Certification

  • Internal Medicine
  • Oncology

Diseases & Conditions Treated

  • Adult Lymphoma
  • Advanced Prostate Cancer
  • All Cancers and Hematological Conditions
  • Cutaneous T-cell Lymphoma (CTCL)
  • HIV Infection and AIDS
  • Prostate Cancer
  • Sarcoma
  • Urologic Cancers


  • Adults


  • Apheresis
  • Blood Transfusion
  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Bone Marrow Transplantation (BMT)
  • Chemotherapy
  • Conscious Sedation
  • Infusional Therapies
  • Lumbar Puncture
  • Paracentesis
  • Stem Cell Collection Procedures
  • Stem Cell Transplantation
  • Thoracentesis
  • Vaccine Therapy for Advanced Prostate Cancer

Current Hospital Privileges

  • Upstate University Hospital

HealthLinkOnAir Radio Interview

5/21/14 How close are we to a cure for HIV?


Link to PubMed External Icon (Opens new window. Close the PubMed window to return to this page.)

Research Abstract

Our laboratory''s primary focus is the detection, quantification, and characterization of human retroviruses. Studies also involve the in vitro and in vivo testing of antiviral compounds. A secondary focus is the role of sarcomeric proteins in cardiomyocyte and cancer cell biology.

Selected References

Walter M. Stadler, Apurva Desai, David Quinn, Ronald Bukowski, B. Poiesz?, C. Kardinal, N. Lewis, A.. Makalinao, Peter Murray, David Quinn, Frank Torti: A Phase I/II Study of GTI-2040 and Capecitabine in Patients with Renal Cell Carcinoma. Cancer Chemotherapy and Pharacology. (in press)

Bernstein ZP, Doughert T, Gollnick S, Schwartz SA, Mahajan SD, Kepner J, Sumlin A, Stewart C, Wallace P, Walder H, and Poiesz B,  Photopheresis in HIV-1 infected patients utilizing Benzoporphyrin Derivatives Verteporfin and light.  Current HIV Research.  6:152-163, 2008.  

Gopaluni S, Perzova R, Abbott L, Farah R, Shrimpton A, Hutchison R, and Poiesz B.  CD8+ Cutaneous T-cell lymphoma successfully treated with Bexarotene: a case report and review of the literature.  Am J Hematol.  83:744-6, 2008.  

Jasti S, Coyle T, Gentile T, Rosales L, and Poiesz B.  Rituxamab as an adjunct to plasmapheresis in TTP: a report of 12 cases and review of the literature.  J. Clin Apheresis.  23:151-6, 2008.

Thomas A, Perzova R, Abbott L, Benz P, Poiesz MJ, Dube S, Loughran Jr T, and Poiesz BJ.  LGL leukemia and HTLV.  In press - AIDS RES HUM RETROVIRUSES. 

Harold L. Thurston, Sastry Prayaga, Anish Thomas, Victor Guharoy, Syamalima Dube, Bernard J. Poiesz, and Dipak K. Dube.  Expression of Nkx2.5 in wild type, cardiac mutant, and thyroxine-induced metamorphosed hearts of the Mexican axolotl.  Cardiovascular Toxicology.  9:13-20, 2009.

Esteban E, Poli M, Poiesz B, Ceriani C, Dube S, Guterrez S, Dolcini G, Perez S, Liitzelschwab C, and Juliarena M.  Bovine leukemia virus (BLV) proposed control and eradication program by marker assisted breeding of genetically resistant cattle.  In "Animal Genetics" (L. Rechi, Ed) NOVA, Hapuppage, NY; 2009.


Clinical Profile Shortcut: http://www.upstate.edu/findadoc/poieszb
Faculty Profile Shortcut: http://www.upstate.edu/faculty/poieszb